News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
284,782 Results
Type
Article (18968)
Company Profile (156)
Press Release (265658)
Multimedia
Podcasts (54)
Webinars (1)
Section
Business (73973)
Career Advice (134)
Deals (12590)
Drug Delivery (58)
Drug Development (56288)
Employer Resources (31)
FDA (8891)
Job Trends (6135)
News (147825)
Policy (12188)
Tag
Academia (1098)
Academic (1)
Accelerated approval (6)
Adcomms (21)
Allergies (49)
Alliances (20683)
ALS (71)
Alzheimer's disease (960)
Antibody-drug conjugate (ADC) (116)
Approvals (8901)
Artificial intelligence (133)
Autoimmune disease (20)
Automation (7)
Bankruptcy (92)
Best Places to Work (5688)
BIOSECURE Act (13)
Biosimilars (55)
Biotechnology (121)
Bladder cancer (71)
Brain cancer (26)
Breast cancer (246)
Cancer (1935)
Cardiovascular disease (138)
Career advice (115)
Career pathing (3)
CAR-T (172)
Cell therapy (477)
Cervical cancer (11)
Clinical research (46868)
Collaboration (619)
Compensation (273)
Complete response letters (21)
COVID-19 (1106)
CRISPR (42)
C-suite (157)
Cystic fibrosis (91)
Data (1773)
Denatured (9)
Depression (33)
Diabetes (188)
Diagnostics (1874)
Digital health (8)
Diversity, equity & inclusion (6)
Drug discovery (83)
Drug pricing (46)
Drug shortages (24)
Duchenne muscular dystrophy (89)
Earnings (28841)
Editorial (18)
Employer branding (6)
Employer resources (29)
Events (47750)
Executive appointments (439)
FDA (9763)
Friedreich's ataxia (4)
Frontotemporal dementia (5)
Funding (456)
Gene editing (98)
Generative AI (11)
Gene therapy (351)
GLP-1 (562)
Government (1553)
Grass and pollen (1)
Guidances (26)
Healthcare (8626)
Huntington's disease (19)
IgA nephropathy (25)
Immunology and inflammation (101)
Indications (22)
Infectious disease (1172)
Inflammatory bowel disease (106)
Inflation Reduction Act (3)
Influenza (23)
Intellectual property (59)
Interviews (20)
IPO (6922)
IRA (15)
Job creations (789)
Job search strategy (102)
Kidney cancer (7)
Labor market (9)
Layoffs (221)
Leadership (1)
Legal (1417)
Liver cancer (53)
Lung cancer (283)
Lymphoma (148)
Machine learning (2)
Management (7)
Manufacturing (207)
MASH (57)
Medical device (4394)
Medtech (4397)
Mergers & acquisitions (6025)
Metabolic disorders (530)
Multiple sclerosis (65)
NASH (14)
Neurodegenerative disease (77)
Neuropsychiatric disorders (25)
Neuroscience (1393)
NextGen: Class of 2025 (2407)
Non-profit (1382)
Now hiring (9)
Obesity (289)
Opinion (99)
Ovarian cancer (63)
Pain (63)
Pancreatic cancer (65)
Parkinson's disease (127)
Partnered (10)
Patents (144)
Patient recruitment (91)
Peanut (31)
People (21793)
Pharmaceutical (31)
Pharmacy benefit managers (3)
Phase I (14573)
Phase II (21072)
Phase III (15842)
Pipeline (882)
Policy (61)
Postmarket research (1605)
Preclinical (5599)
Press Release (64)
Prostate cancer (91)
Psychedelics (35)
Radiopharmaceuticals (192)
Rare diseases (352)
Real estate (1579)
Recruiting (14)
Regulatory (10639)
Reports (18)
Research institute (1271)
Resumes & cover letters (18)
Rett syndrome (5)
RNA editing (3)
RSV (15)
Schizophrenia (53)
Series A (88)
Series B (54)
Service/supplier (4)
Sickle cell disease (46)
Special edition (9)
Spinal muscular atrophy (126)
Sponsored (17)
Startups (1585)
Stomach cancer (14)
Supply chain (41)
Tariffs (15)
The Weekly (44)
Vaccines (263)
Venture capitalists (25)
Weight loss (193)
Women's health (12)
Worklife (1)
Date
Today (85)
Last 7 days (559)
Last 30 days (1694)
Last 365 days (21185)
2025 (6861)
2024 (22198)
2023 (23899)
2022 (28769)
2021 (30068)
2020 (25626)
2019 (19119)
2018 (14126)
2017 (15134)
2016 (13220)
2015 (15301)
2014 (10232)
2013 (7489)
2012 (7638)
2011 (7808)
2010 (7101)
Location
Africa (168)
Alabama (32)
Alaska (3)
Arizona (60)
Arkansas (5)
Asia (17496)
Australia (3036)
California (3885)
Canada (962)
China (427)
Colorado (135)
Connecticut (185)
Delaware (94)
Europe (41838)
Florida (522)
Georgia (122)
Idaho (21)
Illinois (255)
India (20)
Indiana (171)
Iowa (3)
Japan (123)
Kansas (40)
Kentucky (19)
Louisiana (3)
Maine (7)
Maryland (520)
Massachusetts (3178)
Michigan (60)
Minnesota (205)
Missouri (62)
Montana (6)
Nebraska (3)
Nevada (36)
New Hampshire (30)
New Jersey (1210)
New Mexico (14)
New York (1098)
North Carolina (651)
North Dakota (8)
Northern California (1792)
Ohio (129)
Oklahoma (7)
Oregon (15)
Pennsylvania (915)
Puerto Rico (2)
Rhode Island (14)
South America (231)
South Carolina (5)
Southern California (1388)
Tennessee (28)
Texas (543)
United States (14430)
Utah (64)
Virginia (82)
Washington D.C. (27)
Washington State (408)
Wisconsin (29)
284,782 Results for "pep therapy".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer
March 17, 2025
·
4 min read
Business
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, and Institut Curie, France’s leading cancer center, announced the dosing of the first patients in a Phase Ib clinical trial evaluating PEP-Therapy’s lead candidate, PEP-010, based on highly encouraging Phase Ia results.
April 25, 2024
·
6 min read
Press Releases
RION Announces First Patient Enrolled in Phase 1b Clinical Study Evaluating Purified Exosome Product™ (PEP™) for Knee Osteoarthritis
March 12, 2025
·
3 min read
Press Releases
Versant Ventures Unveils Pep2Tango Therapeutics Inc.
November 21, 2024
·
4 min read
Press Releases
RION Announces Final Patient Enrolled in the Phase 2 Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers
January 13, 2025
·
5 min read
Press Releases
Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
March 12, 2025
·
11 min read
Drug Development
RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers
RION’s Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU).
January 30, 2024
·
6 min read
Press Releases
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform
August 5, 2024
·
4 min read
Press Releases
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
April 24, 2025
·
9 min read
Collaboration
Merck Eyes Oral Peptide Delivery With Cyprumed Deal Worth up to $493M
Merck has not disclosed which of its peptide therapies it plans to develop oral formulations for.
April 15, 2025
·
2 min read
·
Tristan Manalac
1 of 28,479
Next
